Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study

Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast... Breast Cancer Res Treat (2017) 165:365–373 DOI 10.1007/s10549-017-4336-z CLINICAL TRIAL Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study 1,2 1 1 1 • • • • Claudio Vernieri Monica Milano Alessia Mennitto Claudia Maggi 1 1 1 1 • • • • Benvenuto Ferrari Lucia Rinaldi Roberta Mennitto Claudia Stefanetti 3 1 1 1 • • • • Barbara Re Gabriella Mariani Giulia Bianchi Giuseppe Capri 1,4 Filippo de Braud Received: 5 June 2017 / Accepted: 8 June 2017 / Published online: 14 June 2017 Springer Science+Business Media, LLC 2017 Abstract HER2-negative biology, a higher number of metastatic Background Taxanes are a mainstay in the treatment of sites, and de novo metastatic disease at diagnosis were metastatic breast cancer (mBC). Combination chemother- associated with reduced PFS, while receiving mainte- apy, including platinum–taxens doublets, can improve nance therapy correlated with improved PFS. Overall, tumor responses and progression-free survival (PFS), but is the treatment was quite well tolerated, with 10.2% of associated with more toxicities and an uncertain benefit in patients discontinuing one or both drugs because of terms of overall survival (OS). adverse events (AEs). G3–G4 neutropenia occurred in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study

Loading next page...
 
/lp/springer_journal/antitumor-activity-and-safety-profile-of-weekly-carboplatin-plus-w4jSEoUA5r
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4336-z
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2017) 165:365–373 DOI 10.1007/s10549-017-4336-z CLINICAL TRIAL Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study 1,2 1 1 1 • • • • Claudio Vernieri Monica Milano Alessia Mennitto Claudia Maggi 1 1 1 1 • • • • Benvenuto Ferrari Lucia Rinaldi Roberta Mennitto Claudia Stefanetti 3 1 1 1 • • • • Barbara Re Gabriella Mariani Giulia Bianchi Giuseppe Capri 1,4 Filippo de Braud Received: 5 June 2017 / Accepted: 8 June 2017 / Published online: 14 June 2017 Springer Science+Business Media, LLC 2017 Abstract HER2-negative biology, a higher number of metastatic Background Taxanes are a mainstay in the treatment of sites, and de novo metastatic disease at diagnosis were metastatic breast cancer (mBC). Combination chemother- associated with reduced PFS, while receiving mainte- apy, including platinum–taxens doublets, can improve nance therapy correlated with improved PFS. Overall, tumor responses and progression-free survival (PFS), but is the treatment was quite well tolerated, with 10.2% of associated with more toxicities and an uncertain benefit in patients discontinuing one or both drugs because of terms of overall survival (OS). adverse events (AEs). G3–G4 neutropenia occurred in

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Jun 14, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off